Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Summit Royalties Secures Up to US$50 Million Revolving Credit Facility; Provides Other Corporate Updates
NextSource Materials Announces Updated Feasibility Study Results for Molo Mine Expansion to 150k tpa of SuperFlake Graphite Concentrate
